Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention.

Curr Control Trials Cardiovasc Med · 2001 · PMC59637 · PMID 11806786

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Interestingly, in a subgroup analysis, abciximab showed even more benefit over tirofiban in patients with acute coronary syndromes, whereas tirofiban showed a trend towards a better outcome in patients without acute coronary syndromes [ 106 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.